Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2

Oncohematology Pub Date : 2024-04-02 DOI:10.17650/1818-8346-2024-19-2-101-108

Y. Y. Polyakov, E. Baryakh, E. Misyurina, E. Zhelnova, M. A. Mingalimov, S. A. Kardovskaya, M. Y. Smolyarchuk, T. Tolstykh, T. S. Chudnova, D. D. Ivanova, O. Kochneva, D. V. Lebedev, A. U. Abueva, A. M. Chistov, E. Zotina, I. Samsonova, M. A. Lysenko

{"title":"Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2","authors":"Y. Y. Polyakov, E. Baryakh, E. Misyurina, E. Zhelnova, M. A. Mingalimov, S. A. Kardovskaya, M. Y. Smolyarchuk, T. Tolstykh, T. S. Chudnova, D. D. Ivanova, O. Kochneva, D. V. Lebedev, A. U. Abueva, A. M. Chistov, E. Zotina, I. Samsonova, M. A. Lysenko","doi":"10.17650/1818-8346-2024-19-2-101-108","DOIUrl":null,"url":null,"abstract":"Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.","PeriodicalId":518071,"journal":{"name":"Oncohematology","volume":"104 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncohematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1818-8346-2024-19-2-101-108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估原发性中枢神经系统大 B 细胞淋巴瘤患者对 SARS-CoV-2 的体液免疫反应，发现新冠状病毒感染持续存在

治疗感染新型冠状病毒（COVID-19）的免疫功能低下患者是一项重大挑战。目前，治疗血液恶性肿瘤中持续存在的 COVID-19 还没有统一的方法。有必要为这类患者的管理、化疗方案以及在 SARS-CoV-2 病毒持续存在的情况下治疗 COVID-19 提出建议。医生们面临着病毒持续存在的病例，在漫长的感染过程中出现临床表现，但却没有为病人的监护提供方法建议。随着淋巴组织增生性疾病患者 COVID-19 持续病程的科学数据不断积累，我们计划为这类患者制定治疗 COVID-19 的建议。本文描述了一例合并原发性中枢神经系统大 B 细胞淋巴瘤的患者在化疗期间出现 COVID-19 持续病程的临床病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncohematology

自引率

0.00%

发文量